CymaBay Therapeutics (NASDAQ:CBAY) is scheduled to announce its earnings results after the market closes on Thursday, March 15th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
CymaBay Therapeutics (NASDAQ CBAY) opened at $13.85 on Wednesday. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $717.22, a price-to-earnings ratio of -13.71 and a beta of 1.66. CymaBay Therapeutics has a twelve month low of $3.16 and a twelve month high of $15.59.
In other news, Director Kurt Von Emster sold 173,192 shares of the business’s stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $9.41, for a total transaction of $1,629,736.72. Following the completion of the sale, the director now directly owns 90,000 shares of the company’s stock, valued at approximately $846,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 978,140 shares of company stock valued at $11,761,941 over the last quarter. 15.10% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “CymaBay Therapeutics (CBAY) Scheduled to Post Earnings on Thursday” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3260393/cymabay-therapeutics-cbay-scheduled-to-post-earnings-on-thursday.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.